新诊断非典型脑膜瘤患者接受辅助放疗的剂量-效应关系
本研究回顾性分析了158例接受手术和辅助放疗的新诊断非典型脑膜瘤患者,其中135例资料完整者纳入分析。中位随访56.0个月,中位辅助放疗剂量61.2 Gy(24-34次),中位EQD2为59.16 Gy。多因素分析显示较大肿瘤体积和高核分裂计数与LC、PFS、OS显著降低相关,而较高放疗剂量与LC、PFS、OS显著改善相关;EQD2每增加1 Gy,局部失败、肿瘤进展和死亡分别减少12%、12%和16%。
要点
- 较大肿瘤体积和高核分裂计数与非典型脑膜瘤辅助放疗后LC、PFS、OS显著降低相关。
- 较高放疗剂量与LC、PFS、OS显著改善相关,呈现剂量-效应关系。
- EQD2每增加1 Gy,局部失败、肿瘤进展和死亡分别减少12%、12%和16%。
核心结论
- 非典型脑膜瘤的辅助放疗剂量与局部控制及生存结局存在剂量-效应关系。
研究设计与样本
- 回顾性分析1998年至2018年间接受手术和辅助放疗的158例新诊断非典型脑膜瘤患者,其中135例放疗剂量/分次和病理报告信息完整者纳入分析。
- 将放疗剂量作为连续变量,使用惩罚样条Cox回归模型分析放疗剂量与事件之间的非线性关系。
- 评估局部控制、无进展生存和总生存,并以α/β比值为4 Gy计算2 Gy分次等效生物剂量(EQD2)。
主要发现
- 中位随访时间为56.0个月,中位辅助放疗剂量为61.2 Gy(24-34次每日分次),对应中位EQD2为59.16 Gy。
- 多因素分析中,较大肿瘤体积与LC降低显著相关(P < 0.001)、与PFS降低显著相关(P < 0.001)、与OS降低显著相关(P = 0.006)。
- 多因素分析中,较高核分裂计数与LC降低显著相关(P = 0.002)、与PFS降低显著相关(P = 0.006)、与OS降低显著相关(P = 0.001)。
- 较高的放疗剂量与LC、PFS和OS改善显著相关。
- 放疗对LC、PFS和OS呈剂量依赖性效应,EQD2每增加1 Gy,局部失败减少12%、肿瘤进展减少12%、死亡减少16%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to identify the radiation dose-response relationship in patients with newly diagnosed atypical meningioma (AM) treated with adjuvant radiotherapy (ART) using conventional fractionation. METHODS: In total, 158 patients who underwent surgery and ART between 1998 and 2018 were reviewed. Among these patients, 135 with complete information on radiotherapy (RT) dose/fractionation and pathological reports were analyzed. We entered RT dose as a continuous variable into the Cox regression model using penalized spline to allow for a nonlinear relationship between RT dose and events. Local control (LC), progression-free survival (PFS), and overall survival (OS) were evaluated. The corresponding biological equivalent dose in 2 Gy fractions (EQD2) was calculated using an α/β ratio of 4 Gy. RESULTS: The median follow-up duration was 56.0 months. The median ART dose delivered was 61.2 Gy in 24-34 daily fractions, corresponding to a median EQD2 of 59.16 Gy. In multivariate analysis, larger size and higher mitotic count were associated with significantly reduced LC (P < 0.001 and P = 0.002, respectively), PFS (P < 0.001 and P = 0.006, respectively), and OS (P = 0.006 and P = 0.001, respectively). Meanwhile, a higher RT dose was significantly associated with improved LC, PFS, and OS. Moreover, RT showed a dose-dependent effect on LC, PFS, and OS; local failure, tumor progression, and death were reduced by 12%, 12%, and 16%, respectively, per 1 Gy increase in the dose (EQD2). CONCLUSION: The dose of ART in AM has a dose-response relationship with LC and survival outcomes.
引用
- Kim D, Chang WI, Byun HK, et al. Dose-response relationship in patients with newly diagnosed atypical meningioma treated with adjuvant radiotherapy. J Neurooncol. 2022. PMID: 36469188. doi:10.1007/s11060-022-04206-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。